CuraGen and TopoTarget have launched a Phase II trial of PXD101 for the treatment of acute myelogenous leukemia (AML).
The study is being sponsored by the National Cancer Institute via a clinical trials agreement with CuraGen.
The trial will involve up to 55 patients under the age of 60 with relapsed or refractory AML or over age 60 with new, relapsed or refractory disease. The patients will receive three-week cycles of PXD101 by intravenous infusion. Those showing complete or partial response will continue to be given the drug until disease progression.
